QSAM Biosciences P/E

Quel est le P/E de QSAM Biosciences?

Le P/E de QSAM Biosciences, Inc. est 0.63

Quelle est la définition de P/E?



Le ratio cours / bénéfice est le rapport entre le prix des actions d'une entreprise et le bénéfice par action de l'entreprise calculé sur les douze derniers mois.

The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.

P/E des entreprises dans Health Care secteur sur OTC par rapport à QSAM Biosciences

Que fait QSAM Biosciences?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

Entreprises avec p/e similaire à QSAM Biosciences